Aller au contenu principal
Institution scientifique

Lupin Pharmaceuticals (United States)

Baltimore, US, company

22Publications signalées
439Citations signalées
12Thèmes principaux

Les principaux domaines

Reproductive tract infections researchInhalation and Respiratory Drug DeliveryDrug Solubulity and Delivery SystemsMenstrual Health and DisordersAsthma and respiratory diseasesCannabis and Cannabinoid ResearchHerpesvirus Infections and TreatmentsAdvanced Drug Delivery SystemsNail Diseases and TreatmentsCrystallization and Solubility StudiesDiet, Metabolism, and DiseaseGABA and Rice Research

L’évolution annuelle

2005 1
2018 2
2020 4
2021 1
2022 3
2023 6
2024 3
2025 2

Les publications récentes

2025 article OpenAlex

Dectin-1 receptor-targeted β-glucan microparticles as dry powder inhalation system – a novel strategy to improve lung pharmacokinetics of rifampicin

Hemali M. Savla, Pramod Gupta, Savita G. Kulkarni, Pinky R Singh et autres

Tuberculosis (TB) remains a global health concern due to complex and lengthy treatment, suboptimal drug concentrations in alveolar macrophages (AMs) and increasing drug resistance. This study investigates dectin-1 receptor-targeted dry powder inhalation (DPI) system for rifampicin (Rif) using β-glucan microparticles (GMPs) for …

in, us (code pays fourni par la source)

1 citation Journal of drug targeting
Accès ouvert 2024 article OpenAlex

Lesson from nature: Zataria multiflora nanostructured lipid carrier topical gel formulation against Candida-associated onychomycosis, a randomized double-blind placebo-controlled clinical trial

Maryam Moazeni, Hamidreza Kelidari, Yaser Nasirzadehfard, Tahereh Shokohi et autres

The increasing resistance to onychomycosis treatment globally is a major concern as it results in treatment failures. This research aimed to investigate the effectiveness of incorporating nanostructured lipid carriers (NLCs) in a gel formulation for treating mild to moderate Candida-associated onychomycosis using …

ir, gb, us (code pays fourni par la source)

7 citations Medicine in Drug Discovery
Accès ouvert 2024 article OpenAlex

Compatibility study of formoterol fumarate-lactose dry powder inhalation formulations: Spray drying, physical mixture and commercial DPIs

Aiesheh Gholizadeh‐Hashjin, Farnaz Monajjemzadeh, Taravat Ghafourian, Hamed Hamishehkar et autres

Formoterol fumarate (FF) is a long-acting beta-adrenergic receptor agonist that is administered as a dry powder inhaler (DPI) for chronic respiratory conditions. In most DPI formulations, the drug substance and the carrier are the two major components. Lactose is the most common …

ir, us, gb (code pays fourni par la source)

12 citations Journal of Drug Delivery Science and Technology
Accès ouvert 2024 article OpenAlex

Harnessing Nanotechnology for Optimized Herbal Cancer Treatment: A Comprehensive Review of Nanoscale Drug Delivery Systems

Malihe Sadat Razavi, Fatemeh Ahmadi, Pedram Ebrahimnejad, Abolfazl Akbarzadeh et autres

Cancer is widely recognized as the second leading cause of death on a global scale. In recent years, nanotechnology has emerged as a promising strategy in the field of cancer therapy. Nanoscale drug delivery systems, a category of innovative technologies, harness the …

ir, us, gb (code pays fourni par la source)

10 citations Pharmaceutical Sciences
Accès ouvert 2023 article OpenAlex

Micro- and nanoformulations of antibiotics against Brucella

Mehran Alavi, Ali Nokhodchi

Brucellosis, a zoonotic intracellular bacterial infection primarily transmitted through the consumption of unpasteurized milk from infected animals, remains a challenging condition to clinically control. This is mainly because of the limited effectiveness of conventional antibiotics in targeting intracellular Brucella. Micro- and nanoformulations …

ir, gb, us (code pays fourni par la source)

6 citations Drug Discovery Today
Accès ouvert 2023 article OpenAlex

Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data

Christina A. Muzny, Olivia T. Van Gerwen, Gregory Kaufman, Steven E. Chavoustie

OBJECTIVES: Bacterial vaginosis (BV) and trichomoniasis are the most common causes of vaginitis. Both infections are associated with increased risk of acquisition and transmission of HIV and other sexually transmitted infections as well as adverse reproductive health outcomes. Co-infection is common, with …

us, in (code pays fourni par la source)

1 citation BMJ Open
Accès ouvert 2023 article OpenAlex

Development, recent advances, and updates in binary, ternary co-amorphous systems, and ternary solid dispersions

Arezoo Saberi, Maryam Kouhjani, Davood Yari, Afsaneh Jahani et autres

Binary co-amorphous systems (CAMS) are a type of solid dispersion containing an active pharmaceutical ingredient (API) and small molecule excipients. The properties of these substances make them novel and a very demanding aspect of pharmaceutical research because they improve solubility, physical stability, …

ir, gb, us (code pays fourni par la source)

45 citations Journal of Drug Delivery Science and Technology
Accès ouvert 2023 article OpenAlex

Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique

Azin Jahangiri, Ali Nokhodchi, Kofi Asare‐Addo, Erfan Salehzadeh et autres

Upregulation of cyclooxygenase (COX-2) plays an important role in lung cancer pathogenesis. Celecoxib (CLX), a selective COX-2 inhibitor, may have beneficial effects in COVID-19-induced inflammatory storms. The current study aimed to develop carrier-free inhalable CLX microparticles by electrospraying as a dry powder …

ir, gb, us (code pays fourni par la source)

7 citations Biomedicines
Accès ouvert 2023 article OpenAlex

In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances

Ali Nokhodchi, Salonee Chavan, Taravat Ghafourian

In vitro dissolution and permeability testing aid the simulation of the in vivo behavior of inhalation drug products. Although the regulatory bodies have specific guidelines for the dissolution of orally administered dosage forms (e.g., tablets and capsules), this is not the case …

gb, us (code pays fourni par la source)

32 citations Pharmaceutics
Accès ouvert 2022 article OpenAlex

Enhanced treatment in cutaneous dermatophytosis management by Zataria multiflora-loaded nanostructured lipid carrier topical gel: A randomized double-blind placebo-controlled clinical trial

Yaser Nasirzadeh Fard, Hamidreza Kelidari, Armaghan Kazeminejad, Seyed Jaber Mousavi et autres

The global rising incidence of skin mycosis especially dermatophytes currently affects more than 20–25% of the world population. It is believed that nanotechnology can aid in the efficient treatment of this skin disease. The present study, therefore, aimed to employ nanostructured lipid …

ir, gb, us (code pays fourni par la source)

11 citations Journal of Drug Delivery Science and Technology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.